9969 Stock Overview
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
InnoCare Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.08 |
| 52 Week High | HK$7.49 |
| 52 Week Low | HK$4.03 |
| Beta | 1.05 |
| 11 Month Change | 20.63% |
| 3 Month Change | 26.14% |
| 1 Year Change | 2.18% |
| 33 Year Change | -71.12% |
| 5 Year Change | n/a |
| Change since IPO | -55.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9969 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 5.6% | 8.5% | 10.9% |
| 1Y | 2.2% | -7.9% | 13.4% |
Return vs Industry: 9969 exceeded the Hong Kong Biotechs industry which returned -7.9% over the past year.
Return vs Market: 9969 underperformed the Hong Kong Market which returned 13.4% over the past year.
Price Volatility
| 9969 volatility | |
|---|---|
| 9969 Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in HK Market | 13.8% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 9969's share price has been volatile over the past 3 months.
Volatility Over Time: 9969's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,109 | Jasmine Cui | www.innocarepharma.com |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma.
InnoCare Pharma Limited Fundamentals Summary
| 9969 fundamental statistics | |
|---|---|
| Market cap | HK$12.54b |
| Earnings (TTM) | -HK$521.96m |
| Revenue (TTM) | HK$865.39m |
12.4x
P/S Ratio-20.5x
P/E RatioIs 9969 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9969 income statement (TTM) | |
|---|---|
| Revenue | CN¥780.73m |
| Cost of Revenue | CN¥112.50m |
| Gross Profit | CN¥668.22m |
| Other Expenses | CN¥1.14b |
| Earnings | -CN¥470.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 85.59% |
| Net Profit Margin | -60.31% |
| Debt/Equity Ratio | 23.2% |
How did 9969 perform over the long term?
See historical performance and comparison